Traditional SDS-PAGE method and its modern equivalent CE-SDS method are both widely applied to assess the purity of therapeutic monoclonal antibody (mAb) drug products. However, structural identification of low molecular weight (LMW) impurities using those methods has been challenging and largely based on empirical knowledges. In this paper, we present that hydrophilic interaction chromatography (HILIC) coupled with mass spectrometry analysis is a novel and orthogonal method to characterize such LMW impurities present within a purified mAb drug product sample. We show here that after removal of N-linked glycans, the HILIC method separates mAb-related LMW impurities with a size-based elution order. The subsequent mass measurement from a high-resolution accurate mass spectrometer provides direct and unambiguous identification of a variety of low-abundance LMW impurities within a single LC-MS analysis. Free light chain, half antibody, H2L species (antibody possessing a single light chain) and protein backbone-truncated species can all be confidently identified and elucidated in great detail, including the truncation sites and associated post-translational modifications. It is worth noting that this study provides the first example where the H2L species can be directly detected in a mAb drug product sample by intact mass analysis without prior enrichment.
Introduction
Monoclonal antibodies (mAbs) have been successfully employed to target a wide range of therapeutic areas over the last two decades [1, 2] . While mAbs possess a conserved covalent heterotetrameric structure consisting of two disulfidelinked heavy chains, each covalently linked through a disulfide bond to a light chain, these proteins often contain low levels of product-related impurities even after extensive purification steps. Low molecular weight (LMW) species (e.g. protein backbonetruncated fragments) and high molecular weight (HMW) species (e.g. antibody dimer species) are both examples of product-related impurities that contribute to the size heterogeneity of mAb products. The formation of HMW species within a therapeutic mAb drug product as a result of protein aggregation can potentially compromise both drug efficacy and safety (e.g. eliciting unwanted immunogenic response) [3, 4] . LMW species often have low or substantially reduced activity relative to the monomeric form of the antibody, while exposing novel epitopes that can lead to immunogenicity or potentially impact pharmacokinetic properties in vivo [5] . As a result, both HMW and LMW species are considered critical quality attributes that are routinely monitored during drug development and as part of release testing of purified drug product during manufacturing.
Molecular weight heterogeneity of mAb products is traditionally characterized by multiple orthogonal analytical methods [6] . For example, SDS-PAGE performed under non-reducing conditions, has been regularly used to assess mAb product purity. During analysis, minor bands corresponding to LMW species can be routinely observed and quantified, including H2L (2 heavy chains and 1 light chain), H2 (2 heavy chains), HL (1 heavy chain and 1 light chain), HC (1 heavy chain), and LC (1 light chain) species [7] . The proposed identity of each minor band can be supported by N-terminal sequencing via Edman degradation, in-gel tryptic digestion followed by mass spectrometry analysis, and western blot analysis using anti-Fc and anti-light chain antibodies. However, any proposed structures resulting from these methods cannot be unambiguously confirmed at the intact protein level. Furthermore, sample preparation conditions employed in SDS-PAGE experiments can generate LMW artifacts through disulfide bond scrambling, which can lead to overestimation of LMW species [8] . More recently, capillary electrophoresis-sodium dodecyl sulfate (CE-SDS) has emerged as a modern equivalent of SDS-PAGE, offering superior reproducibility, sensitivity, and throughput [9] [10] [11] . During CE-SDS analysis of mAb products, minor peaks with shorter migration times (LMW forms) than the intact antibody can be routinely observed. Unlike SDS-PAGE analysis, these LMW impurities cannot be extracted or subjected to further analyses. As a result, the identities of LMW impurities observed in CE-SDS methods are often proposed solely based on empirical knowledge. Thus, an orthogonal method to directly separate and unambiguously identify the LMW impurities in mAb products is critically needed to better understand the drug products and ensure control of the manufacturing process.
Accurate mass measurement of intact mAb proteins by modern mass spectrometers has become increasingly popular in the biopharmaceutical industry as one of the most reliable identification techniques [12, 13] . Specifically, a variety of "hyphenated chromatography-mass spectrometry" methods have demonstrated the capability of detecting low-abundance impurities in mAb products and providing highly detailed analyses that cannot be achieved by either SDS-PAGE or CE-SDS methods [14, 15] . For example, reversed-phase chromatography (RPLC) coupled to mass spectrometry can be used to detect free light chain and associated post-translational modifications (e.g. cysteinylation and glutathionylation) present in mAb drug products. However, compared to SDS-PAGE and CE-SDS methods, RPLC often lacks sufficient resolution to separate LMW species and thus fails to elucidate the complete LMW profile. For example, the identification of H2L species in mAb drug products has never been reported by RPLCbased intact mass analysis, owing to its low abundance and poor resolution from the main intact antibody. Another MS-based technique that is promising for characterizing mAb product-related impurities is native electrospray ionization mass spectrometry (Native ESI-MS), which is particularly informative when coupled with size exclusion chromatography (SEC) [15] . However, the LMW species identified in native SEC-MS analysis are often not the same as those identified by SDS-PAGE or CE-SDS, due to significantly different experimental conditions used between methods. Specifically, the sample preparation required for SDS-PAGE and CE-SDS often starts with protein denaturation, where the non-covalent interactions between the N-terminal regions of HC-LC pairs and the C-terminal regions of the HC-HC pairs are disrupted. As a result, LMW impurities such as H2L, half antibody, and free light chain species are able to dissociate from the mAb molecule if the interchain disulfide bonds are broken. In comparison, native SEC-MS analyzes the mAb samples under near native conditions, permitting the strong non-covalent interchain interactions to be preserved and allowing the four-chain structure of the mAb molecule to be maintained even if the interchain disulfide bonds are broken. Although advances in SEC column chemistry have made it possible to use denaturing buffers (e.g. 30% acetonitrile, 0.1% FA and 0.1% TFA) that are normally used in reversed-phase chromatography for SEC separation and direct coupling to online mass spectrometry analysis [16] , the LC resolution is still sub-optimal for detecting many LMW species.
In this study, we developed a novel method using hydrophilic interaction chromatography (HILIC) coupled to mass spectrometry analysis to directly characterize LMW impurities in mAb products. We show that after removal of the N-linked glycans from each heavy chain of the antibody, the elution of LMW impurities from the HILIC column is mostly determined by the size of the molecular weight species. In addition, the HILIC separation is performed under denaturing conditions, making the detection of LMW forms using this method highly comparable to both SDS-PAGE and CE-SDS methods. Using a recombinant IgG1 mAb drug product sample as an example, we demonstrate that this newly developed HILIC-MS method can effectively separate and detect many low-abundance LMW impurities in a single LC-MS analysis, including free light chain, half antibody, H2L species and protein backbone-truncated species. Specifically, the study provides the first example where the H2L species can be directly detected in a mAb drug product sample by intact mass analysis without prior enrichment.
Material and methods

Material
For this study, a recombinant IgG1 mAb (mAb-1) made by Regeneron (Tarrytown, NY) was used.
Peptide-N-Glycosidase F (PNGase F, # P0704L) was purchased from New England Biolabs (Ipswich, MA), 1 M Tris-hydrochloride pH 7.5 solution (# 15567-027) was purchased from Invitrogen (Carlsbad, CA), dithiothreitol (DTT, #20291) was purchased from Thermo Fisher Scientific (Waltham, MA), and l-cysteine (#168149-25G) was purchased from Sigma-Aldrich (St. Louis, MO). Acetonitrile (LC-MS grade, #A955-4) and trifluoroacetic acid (TFA, #PI28904) were purchased from Fisher Scientific (Hampton, NH). Milli-Q water was provided in-house.
Deglycosylation of mAb-1 and limited reduction by DTT and l-cysteine
The mAb-1 sample was diluted to a final concentration of 5 g/L using 100 mM Tri-HCl (pH 7.5). PNGase F was added at an enzyme to substrate ratio of 1 unit/10 g protein. The deglycosylation reaction was conducted at 37 • C for 3 h and the deglycosylated mAb-1 sample was then injected onto the HILIC column for online UV and mass spectrometry analysis. To initiate the limited reduction by DTT, a 20 g aliquot of the deglycosylated mAb-1 sample was reduced with 5 mM DTT before immediate injection onto the HILIC column for online UV and mass spectrometry analysis. To initiate the limited reduction by l-cysteine, a 20 g aliquot of the deglycosylated mAb-1 sample was reduced with 5 mM l-cysteine at 37 • C for 30 min before injection onto the HILIC column for online UV and mass spectrometry analysis. The injection volume was 1.5 L for all samples.
HILIC-UV and HILIC-MS analysis
A Waters ACQUITY UPLC Glycoprotein Amide column (300 Å, 1.7 m, 2.1 × 150 mm) was used on a Waters ACQUITY UPLC system for all HILIC separations (Waters, Milford, MA). The column was operated at 60 • C. The mobile phases were 0.1% TFA in water as A, 0.1% TFA in acetonitrile as B, and the flow rate was set to 0.2 mL/min. The UV traces were recorded at 215 and 280 nm. The separation was achieved over 55 min with an initial 0.5 min hold at 15% A, followed by an increase to 25% A over the next 0.5 min, and another linear increase to 40% A over the next 40 min. The gradient was then ramped to 100% A over 1 min and held for 2 min, before dropping to 15% A in 1 min, and then maintained at initial condition for over 10 min to equilibrate the column for the next run. The UPLC was directly coupled to a Thermo Scientific Q Exactive hybrid quadrupole Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA). The capillary voltage was set at 4.0 kV, with a sheath gas flow rate of 40 arbitrary units and auxiliary gas flow rate of 15 arbitrary units. The capillary temperature was set at 350 • C and the probe heater temperature was set at 400 • C. Mass spectra were acquired in the mass range of m/z 800-4000. The raw data were deconvoluted using Intact Mass TM software developed by Protein Metrics (San Carlos, CA). 
Results and discussion
In this study, a recombinant IgG1 mAb (mAb-1) drug product sample was used as a model molecule. After treatment with PNGase F to remove N-linked glycans on each heavy chain, the deglycosylated mAb-1 sample was separated on a HILIC column and analyzed by both photodiode array (PDA) detection (at both 280 nm and 215 nm) and mass spectrometry analysis (Fig. 1) . As shown in the UV profile (Fig. 1, black trace) , the overall level of LMW impurities in mAb-1 drug product sample was very low, suggesting a successful purification process. By comparing the total ion chromatogram (TIC) generated from mass spectrometry analysis to the UV chromatogram, an additional peak (with a retention time at ∼18.2 min) was observed in the TIC trace, which corresponded to the major glycan form (G0F) released from mAb-1 by PNGase F. As oligosaccharides do not exhibit UV absorption at either 280 nm or 215 nm, they are invisible in UV detection. In addition to the PNGase F reagent peak, all other minor peaks were identified as mAb-1 related LMW impurities, specifically, free light chain (with multiple modifications), Fab fragments, half-antibody, Fab-truncated species and H2L species (Fig. 1) . The elution order of these LMW impurities on the HILIC column was correlated with their relative sizes, with smaller fragments eluting earlier than the larger fragments. It is important to note that removing the N-linked glycans from the mAb molecule is essential before this analysis. Otherwise, the size-based elution order on the HILIC column will be complicated by the presence or absence of glycans and the different glycoforms.
Free light chain
Multiple light chain-related impurities were detected in HILIC-MS analysis of the mAb-1 sample (Fig. 2) . The extracted ion chromatograms (XICs) of each species suggested that they also exhibited different retention times during HILIC separation (Fig. 2,  top panel) . Interestingly, the cysteinylated light chain (+∼119 Da) was identified as the major form of all light chain species present in mAb-1 sample and it is the only light chain species visible by UV (Fig. 2c) . The cysteinylation may occur as a result of the thiol-disulfide exchange reaction between the inter-heavy and light chain disulfide bond and a free cysteine molecule, which was introduced as an essential amino acid in cell culture. In addition, glutathionylated light chain (+∼306 Da) was also identified, with a retention time slightly later than the cysteinylated light chain (Fig. 2d) . Similar to the cysteinylation process, free glutathione (GSH) molecule, which can also be found in cytoplasm, should be responsible for this modification. Another interesting LC variant with a delta mass of +∼90 Da from predicted mass was also observed (Fig. 2b) . Subsequent peptide mapping analysis using recombinant Lys-C protease located this modification to the light chain C-terminal Cys residue. Based on accurate delta mass (+89.98 Da) and isotopic distribution, we speculate that this modification was a result of the thiol-disulfide exchange reaction between the inter-heavy and light chain disulfide bond and a 2-mercaptoacetic acid molecule (Supplementary Material). However, how this compound was introduced or generated during mAb production is currently under investigation. Although invisible in the UV trace, unmodified free light chain can also be detected by more sensitive mass spectrometry analysis, along with a group of light chain variants corresponding to the sequential clipping of the C-terminal amino acid residues (Fig. 2b) . The resulting amino acid ladder as shown in the deconvoluted mass spectrum (Fig. 2b) matched with the C-terminal sequence of light chain (Gly-Glu-Cys). The removal of C-terminal amino acid residues from the light chain might be attributed to the presence of some carboxyl peptidases in the cell culture [17, 18] . Finally, another light chain variant with a mass decrease of ∼34 Da was also identified (Fig. 2a) , suggesting possible cysteine to dehydroalanine conversion via ␤-elimination on the light chain C-terminal Cys residue. This reaction has been well studied previously and identified as a major pathway for subsequent truncation at the antibody hinge region during storage [19] . It is noteworthy all those light chain related impurities are not likely to be detected by SEC method under native conditions, as they can still bind to the heavy chain via a strong non-covalent interaction despite the broken inter-heavy and light chain disulfide bond. Thus, the denaturing conditions used in this HILIC separation are critical in successful detection of those impurities. 
Fab fragment
It is well known that the upper hinge region of heavy chains in an IgG1 molecule is susceptible to hydrolysis [20] , leading to the formation of two complementary LMW species, a Fab fragment and a Fab-truncated species. The HILIC-MS method detected both species in the mAb-1 sample. Four major Fab fragments with different masses were identified (Fig. 3a) and the truncation sites were located by comparing the measured masses with the predicted masses, based on the cDNA-derived amino acid sequence. The amino acid pattern indicated in the deconvoluted mass spectrum matched with the heavy chain hinge region sequence (Cys-Asp-LysThr-His-Thr-Cys). It is worth noting that any Fab fragment should have been readily removed during the purification process due to the lack of the Protein A binding site. Therefore, the presence of Fab fragments in the final drug product sample indicated that those impurities were introduced as degradation products during sample storage. The successful detection of those species emphasizes that the HILIC-MS method would be useful in stability and forced degradation studies during mAb drug development.
Half antibody
Half antibody is formed as a result of inter-heavy and heavy chain disulfide bonds at the hinge region scrambling into intra-heavy chain disulfide bonds. Under native conditions, the four-chain structure of a mAb molecule remains undisrupted by this scrambling, owing to the strong non-covalent interaction between the two heavy chain C-terminal regions. However, when a method with denaturing conditions is used, such as SDS-PAGE or CE-SDS, the two half antibody molecules will dissociate from each other and appear as LMW impurities. During the HILIC-MS analysis of mAb-1 product, the half antibody molecule was confidently identified (Fig. 3b) . The good agreement between the measured mass (73,099.5 Da) and the predicted mass (73,100.1 Da) suggested that, unlike extensively modified free light chain, no substantial modification was associated with the formation of the half antibody, consistent with the disulfide bond scrambling pathway.
Fab-truncated species
As the complementary fragments to the Fab fragments after heavy chain hinge region truncation, Fab-truncated species were also identified in mAb-1 sample by the HILIC-MS method (Fig. 3c) . On the HILIC column, those species eluted right before the main peak as a partially resolved shouldering peak. The subsequent mass measurement confirmed the identity of the Fab-truncated species and truncation sites were located at the hinge region consistent with those observed in the Fab fragments. Despite the inferior resolution in separation compared to electrophoretic methods, the HILIC-MS method prevails in high fidelity and specificity by accurate mass measurement, making unambiguous identification possible. Unlike the Fab fragments, the Fab-truncated species are very difficult to remove from the main species during purification, due to the preserved Fc region that binds to Protein A. Monoclonal antibody molecules missing a Fab arm are expected to exhibit compromised potency as one of the two target binding sites is not present. For bispecific mAb molecules, losing one Fab arm is detrimental for drug activity, since both Fab arms are essential to achieve the designed therapeutic functions. Therefore, the ability Fig. 4 . The HILIC-UV analysis of deglycosylated mAb-1 sample treated by DTT (red trace) and l-cysteine (blue trace). The signal of untreated sample and l-cysteine treated sample were amplified 10 times and 2 times, respectively, to better visualize the LMW impurities. to detect and identify those species directly in a drug product sample is highly important because not only are time and resources saved, but the possible introduction of LMW artifacts during the enrichment process can also be avoided.
H2L species
The H2L species, comprised of two heavy chains and one light chain, are frequently observed as the most abundant LMW impurities by SDS-PAGE and CE-SDS methods, but their identification is usually only supported by indirect and insufficient evidence. For example, N-terminal sequencing analysis of the H2L-containing minor band on SDS-PAGE can reveal the first several amino acid residues of both heavy chain and light chain, and the signal intensity ratio between heavy chain and light chain might suggest a 2 to 1 ratio. In-gel digestion of the H2L-containing minor band followed by LC-MS based peptide mapping analysis can confidently confirm the presence of both heavy chain and light chain. However, it is difficult to establish an accurate ratio between heavy chain and light chain. Both methods provide partial identification of H2L species, but neither can reveal a complete structure. In contrast, HILIC-MS method offers direct identification of H2L species at the intact protein level. In mAb-1 product, a homogeneous H2L species was observed to co-elute with the Fab-truncated species slightly ahead of the intact antibody. The detected mass (122,851.0 Da) of the H2L species was approximately 34 Da smaller than the predicted molecular weight of a H2L molecule (122,884.5 Da). We speculate that the ␤-elimination of a heavy chain cysteine residue, presumably the one originally forming the inter-heavy and light chain disulfide bond, was the root-cause of forming H2L species in mAb-1 sample. This level of confidence and detailed information cannot be achieved by other well-established purity assays, making this method very valuable in providing essential identification for those LMW impurities. To the best of our knowledge, this study is the first case where H2L species is shown to be directly detected by intact mass analysis in a mAb drug product sample without prior enrichment.
LMW impurities generated under forced conditions by limited reduction
Comparing to the HILIC-MS analysis of the mAb-1 sample, SDS-PAGE and CE-SDS methods frequently identified more LMW impurities, including the heavy chain dimer and free heavy chain. In order to demonstrate the capability of the new HILIC method in detecting those impurities, the deglycosylated mAb-1 sample was further treated with reductant (dithiothreitol (DTT) and l-cysteine) under native conditions to facilitate the formation of various LMW impurities. It has been reported that under native conditions, only inter-chain disulfide bonds in a mAb molecule can be reduced by DTT, since they are the only solvent-accessible disulfide bonds in the molecule [21] . After briefly exposing mAb-1 molecule to DTT or l-cysteine, LMW impurities with different heavy chain and light chain combinations can be generated, including free light chain, free heavy chain, half antibody, heavy chain dimer and H2L species. As shown in Fig. 4 , these predicted LMW species were detected in the HILIC separation with the elution order consistent with their relative size. In addition to those observed in the untreated mAb-1 sample, two more LMW species, specifically, the free heavy chain species and the heavy chain dimer species, were observed to elute between the free light chain and half antibody, and slightly after the half antibody (partially resolved peak), respectively. In addition to elution order-guided assignment, the subsequent mass spectrometry analysis following HILIC separation further confirmed the identity of each impurity based on accurate mass (Fig. 5) . Interestingly, the light chain species in the DTT-treated mAb-1 sample exhibited a very different retention time than the light chain species observed in the untreated sample (Fig. 4) . Based on the accurate mass measurement, the difference in retention time was attributed to the cysteinylation on light chain that was present in the untreated sample but absent in the DTT-treated sample. Consistently, when mAb-1 was treated with l-cysteine, a small fraction of the light chain species was observed at the same retention time as the light chain species in the untreated sample, suggesting the occurrence of cysteinylated light chain in the l-cysteine-treated sample. Finally, the measured mass of H2L species in DTT-treated sample (122,884.5 Da) was in agreement with the predicted mass of the unmodified H2L species (122,884.5 Da) because it is predominantly composed of the H2L species generated via disulfide bond reduction (predicted mass: 122,884.5 Da) and low levels of preexisting H2L species generated via ␤-elimination (predicted mass: 122,850.4 Da).
Conclusions
Product-related impurities are considered critical quality attributes in therapeutic mAb products and need to be monitored across the drug development process, including in QC release testing. Traditional electrophoretic methods such as SDS-PAGE and CE-SDS have been widely applied in the biopharmaceutical industry and accepted by regulatory agencies, due to their excellent reproducibility and robustness. Although those methods are sufficient for batch-to-batch comparability tests, they are less useful in out-of-trend (OOT) or out-of-specification (OOS) analyses, due to limited identification information provided. We have demonstrated that the HILIC-MS method can provide those detailed identification information, making it a valuable addition to our assay portfolio. The reliable identification and detailed structural information revealed by HILIC-MS analysis can also be highly valuable for in-depth characterization of LMW impurities in mAb products, which is often required for late-stage molecule development. Furthermore, as the HILIC-MS method uses a gentler sample preparation than either SDS-PAGE or CE-SDS does, it is less likely to generate LMW artifacts. However, as shown in this study, the resolution of the current HILIC method is inferior to the electrophoretic methods with regards to separating the different LMW impurities. For example, the baseline separation between the H2L species and main species cannot be achieved, which makes accurate quantitation very challenging. Nevertheless, the HILIC-MS method can still be used as a semi-quantitative analysis to compare the LMW impurity profile between samples or simply applied qualitatively. With the ever advancing column technology, it is possible that higher-resolution HILIC method may one day be available, achieving a more comprehensive LMW impurity characterization for mAb products.
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